Related Experiment Video

Updated: Jun 26, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
07:46

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat

Published on: June 4, 2012

Methicillin resistant Staphylococcus aureus endocarditis in an Australian tertiary hospital: 1991-2006

Benjamin A Rogers1, Anne K Drake, Denis Spelman

  • 1Victorian Infectious Diseases Service, The Royal Melbourne Hospital, Grattan Street, Parkville 3050, Victoria, Australia. benrogers@netspace.net.au

Heart, Lung & Circulation
|January 3, 2009
PubMed
Abstract

Insights

Methicillin-resistant Staphylococcus aureus (MRSA) endocarditis in Australia predominantly affects older patients with comorbidities. Despite aggressive treatment, mortality remains high, underscoring the need for new therapeutic strategies.

Area of Science:

  • Infectious Diseases
  • Cardiology
  • Public Health

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) endocarditis presents a growing clinical challenge with significant mortality.
  • This study addresses a gap in understanding MRSA endocarditis within the Australian healthcare landscape.

Purpose of the Study:

  • To characterize MRSA endocarditis patients in Australia.
  • To analyze treatment modalities and outcomes over a 16-year period.
  • To identify epidemiological trends in MRSA endocarditis acquisition.

Main Methods:

  • A retrospective case series design was employed.
  • Data were collected from 1991 to 2006.
  • Patient demographics, comorbidities, acquisition sources, management, and outcomes were analyzed.

Main Results:

  • Twenty-seven patients with MRSA endocarditis were identified, with a median age of 64.
  • The majority of infections were healthcare-associated (nosocomial or non-nosocomial).
  • High mortality (66%) was observed despite combination antibiotic therapy and surgical intervention.

Conclusions:

  • MRSA endocarditis in Australia is characterized by older patients with comorbidities, often acquired in healthcare settings.
  • Current treatment strategies, including combination antibiotics and surgery, yield high mortality rates.
  • Further research, particularly randomized controlled trials for antibiotic therapies, is warranted.

Related Concept Videos

Endocarditis I: Introduction01:25

Endocarditis I: Introduction

Introduction:Endocarditis is the infection of the endocardium, the inner lining of the heart and its valves. When the heart muscle is involved, the condition is termed myocarditis, while an infection of the outer lining is called pericarditis. Infective endocarditis (IE) primarily affects the endocardium, where pathogens adhere to the valves or lining, forming vegetation that can lead to severe complications. Infective endocarditis occurs when microorganisms, usually bacteria from other body...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...